175 related articles for article (PubMed ID: 20573084)
1. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
Nath CE; Shaw PJ; Trotman J; Zeng L; Duffull SB; Hegarty G; McLachlan AJ; Gurney H; Kerridge I; Kwan YL; Presgrave P; Tiley C; Joshua D; Earl J
Br J Clin Pharmacol; 2010 May; 69(5):484-97. PubMed ID: 20573084
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Mizuno K; Dong M; Fukuda T; Chandra S; Mehta PA; McConnell S; Anaissie EJ; Vinks AA
Clin Pharmacokinet; 2018 May; 57(5):625-636. PubMed ID: 28918602
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
5. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Pai AA; Devasia AJ; Panetta JC; Mani S; Stallon Illangeswaran RS; Mohanan E; Balakrishnan B; Lakshmi KM; Kulkarni U; Aboobacker FN; Korula A; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):130-135.e1. PubMed ID: 31791694
[TBL] [Abstract][Full Text] [Related]
7. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
8. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
9. Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation.
Aljitawi OS; Ganguly S; Abhyankar SH; Ferree M; Marks R; Pipkin JD; McGuirk JP
Bone Marrow Transplant; 2014 Aug; 49(8):1042-5. PubMed ID: 24911220
[TBL] [Abstract][Full Text] [Related]
10. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Qazilbash MH; Saliba RM; Nieto Y; Parikh G; Pelosini M; Khan FB; Jones RB; Hosing C; Mendoza F; Weber DM; Wang M; Popat U; Alousi A; Anderlini P; Champlin RE; Giralt S
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1401-7. PubMed ID: 19041063
[TBL] [Abstract][Full Text] [Related]
12. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
[TBL] [Abstract][Full Text] [Related]
15. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma.
Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP
Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high-dose melphalan in adults: influence of renal function.
Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C
Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of melphalan in myeloma patients undergoing an autograft.
Nath CE; Shaw PJ; Trotman J; Zeng L
Bone Marrow Transplant; 2007 Oct; 40(7):707-8. PubMed ID: 17680022
[No Abstract] [Full Text] [Related]
18. Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.
Cho YK; Sborov DW; Lamprecht M; Li J; Wang J; Hade EM; Gao Y; Tackett K; Williams N; Benson DM; Efebera YA; Rosko AE; Devine SM; Poi M; Hofmeister CC; Phelps MA
Clin Pharmacol Ther; 2017 Sep; 102(3):511-519. PubMed ID: 28160288
[TBL] [Abstract][Full Text] [Related]
19. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
[TBL] [Abstract][Full Text] [Related]
20. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
